Matthew Smith, MD
Vascular Surgery · Seattle, WANPI 1942542212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,610 of the $6,097 with a category attached, or 92.0%. Cook Incorporated accounts for 92.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $5,706 and has fallen 96.4% since, to $208 in 2025.
Across 13 payments — averaging $468.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$6K
- Penumbra, Inc.$192
- Shockwave Medical, Inc$83
- Abbott$55
- W. L. Gore & Associates, Inc.$52
- Cook Medical LLC$51
- plus $54 from 2 others
What the payments were for
- Speaking & faculty fees$5,61092%
- Food & beverage$4878%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 1 | $5,610 |
| Penumbra, Inc. | 3 | $192 |
| Shockwave Medical, Inc | 4 | $83 |
| Abbott | 1 | $55 |
| W. L. Gore & Associates, Inc. | 1 | $52 |
| Cook Medical LLC | 1 | $51 |
| Genentech USA, Inc. | 1 | $34 |
| Medtronic | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilver PTX$5,610
- Penumbra System$156
How this compares
$6,097 in reported general payments places this provider in the 60th percentile of 111 vascular surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 18 | $13,506 |
| Cilostazol | 14 | $526 |
| Atorvastatin Calcium | 11 | $213 |
| Rosuvastatin Calcium | 12 | $125 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Seattle
- Sara ZettervallSeattle$126K
- Paul HayesSeattle$83K
- Elina QuirogaSeattle$69K
- Mark MeissnerSeattle$43K
- Niten SinghSeattle$33K
- Matthew SweetSeattle$28K
- Matthew BennettSeattle$23K
- Saideep BoseSeattle$18K
- Jake HemingwaySeattle$15K
- Jose TraniSeattle$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.